Juris J Meier (J J Meier)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 28

Top Topics

Roux En Y Gastric Bypass

Top Venues

Diabetes, obesity & metabolism

Diabetic medicine : a journal of the British Diabetic Association

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel Robert Quast, Dara Lancaster, Cong Xie, Michelle J Bound, Jacqueline Grivell, Karen Louise Jones, Michael Horowitz, Juris J Meier, Chinmay S Marathe, Christopher K Rayner, Michael A Nauck
Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, obesity & metabolism (2024)
Daniel Robert Quast, Dara Lancaster, Cong Xie, Michelle J Bound, Jacqueline Grivell, Karen Louise Jones, Michael Horowitz, Juris J Meier, Chinmay S Marathe, Christopher K Rayner, Michael A Nauck
Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes. Diabetes, obesity & metabolism 26 (9) (2024)
Vanita R Aroda, Umut Erhan, Peter Jelnes, Juris J Meier, Morten Tind Abildlund, Richard E Pratley, Tina Vilsbøll, Mansoor Husain
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, obesity & metabolism (2023)
Daniel Robert Quast, Juris J Meier
Increased incidence of GERD in GLP-1 treated patients: fact or artefact? Gut (2023)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 25 (4) (2023)
Vanita R Aroda, Umut Erhan, Peter Jelnes, Juris J Meier, Morten Tind Abildlund, Richard Pratley, Tina Vilsbøll, Mansoor Husain
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, obesity & metabolism (2023)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 25 (4) (2023)
Laerke Smidt Gasbjerg, Mette Marie Rosenkilde, Juris J Meier, Jens Juul Holst, Filip K Krag Knop
The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes, obesity & metabolism (2023)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism 25 (4) (2023)
Juris J Meier, Daniel Robert Quast, Michael A Nauck, Nina Schenker, Carolyn F Deacon, Jens J Holst, Leona Plum-Mörschel, Christoph Kapitza
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, obesity & metabolism 24 (5) (2022)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism (2022)
Juris J Meier, Charlotte Granhall, Ulrike Hoevelmann, Andrea Navarria, Leona Plum-Moerschel, Chethana Ramesh, Andrea Tannapfel, Christoph Kapitza
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes, obesity & metabolism 24 (4) (2022)
Vanita R Aroda, Robert Bauer, Erik Christiansen, Martin Haluzík, Klaus Kallenbach, Eduard Montanya, Julio Rosenstock, Juris J Meier
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes, obesity & metabolism 24 (7) (2022)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism (2022)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. Diabetes, obesity & metabolism (2022)
Juris J Meier, Lars Bardtrum, Alice Y Y Cheng, Brian Malling, Eduard Montanya, Lily Wagner, Richard E Pratley
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: a post hoc analysis. Diabetes, obesity & metabolism (2022)
Daniel Robert Quast, Michael A Nauck, Nina Schenker, Björn A Menge, Christoph Kapitza, Juris J Meier
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes, obesity & metabolism 23 (10) (2021)
Tina K Thethi, Richard E Pratley, Juris J Meier
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes, obesity & metabolism 22 (8) (2020)
Daniel Robert Quast, Nina Schenker, Björn A Menge, Michael A Nauck, Christoph Kapitza, Juris J Meier
Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. Diabetes care 43 (9) (2020)
Mirna Abd El Aziz, Oscar Cahyadi, Juris J Meier, Wolfgang E Schmidt, Michael A Nauck
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes, obesity & metabolism 22 (4) (2019)
Juris J Meier, Björn A Menge, Nina Schenker, Silke Erdmann, Melanie Kahle-Stephan, Freimut Schliess, Christoph Kapitza, Michael A Nauck
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. Diabetes, obesity & metabolism 22 (4) (2019)
Dario Giugliano, Juris J Meier, Katherine Esposito
Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes, obesity & metabolism 21 (5) (2019)
Daniel Robert Quast, Michael A Nauck, F G Bechara, Juris J Meier
A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers. Diabetic medicine : a journal of the British Diabetic Association 34 (8) (2018)
Michael A Nauck, Juris J Meier
Incretin hormones: Their role in health and disease. Diabetes, obesity & metabolism (2018)
Julio Rosenstock, Yehuda Handelsman, Josep Vidal, F Javier Ampudia Blasco, Francesco Giorgino, Minzhi Liu, Riccardo Perfetti, Juris J Meier
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 20 (12) (2018)
Juris J Meier, Nina Schenker, Melanie Kahle, Freimut Schliess, Christoph Kapitza, Björn A Menge
Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study. Diabetes, obesity & metabolism 19 (11) (2017)
Lena Mumme, Thomas G K Breuer, Stephan Rohrer, Nina Schenker, Björn A Menge, Jens Juul Holst, Michael A Nauck, Juris J Meier
Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. Diabetes care 40 (10) (2017)
Michael A Nauck, Juris J Meier, Wolfgang E Schmidt
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials. Diabetes, obesity & metabolism 19 (9) (2017)